{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-019487","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2022-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.452726+00:00","generated_at":"2026-06-24T13:20:09.427432+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biotricity reports FY22 revenue $7.7M (+126% YoY); Q4 revenue $2.15M (+81%); net loss $30.2M","bullets":["FY22 revenue $7.7M (+126% YoY); gross margin improved to 60% from 38% in FY21.","Q4 FY22 revenue $2.15M (+81% YoY); gross margin 67% vs 60% in Q4 FY21.","FY22 net loss $30.2M ($0.665 per share); adjusted loss per share $0.48.","Cash $12M at March 31, 2022; closed $12M non-convertible debt and extinguished $1.6M legacy debt.","Expanded network to 300+ centers, 1,500 cardiologists; launched Biotres, Bioheart, Biokit after FDA clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-019487","json":"https://secwatch.observer/filing/0001493152-22-019487.json","markdown":"https://secwatch.observer/filing/0001493152-22-019487.md","text":"https://secwatch.observer/filing/0001493152-22-019487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315222019487/0001493152-22-019487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315222019487/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T13:20:09.427432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}